VIVUS (NAS: VVUS) not only beat its competitors, Arena Pharmaceuticals (NAS: ARNA) and Orexigen Therapeutics (NAS: OREX) , in making its obesity drug the first to reach patients -- it's also the first of this trio to report its Q3 earnings.
VIVUS posted its Q3 report before the market opened this morning, and unfortunately for shareholders, the company's results didn't meet the market's expectations. The company's net revenue was expected to top $300,000, but the drugmaker only raked in a little over $40,000. Earnings also took a bigger hit than expected, and VIVUS' shares subsequently plunged almost 25% today.
In the following video, health care analysts Max Macaluso and David Williamson discuss these stagnant sales and three ways that VIVUS can boost revenue in upcoming quarters.
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including the one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.
The article VIVUS Earnings: Is This Biotech Ready for Prime Time? originally appeared on Fool.com.
Max Macaluso, Ph.D. and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Express Scripts. Motley Fool newsletter services recommend Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.